ArticleBlood advances2026
Clinical trial success rate in lymphoma: fate of trials and agents from 2000 to 2019.
Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- From phase 1 to approval: lymphoma's long road.Blood advances · 2026Article
Corrections and comments
- Commented on by
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractAlthough previous studies have examined the drug development and clinical trial success rates in oncology, a comprehensive analysis of development success rate in lymphoma has not been performed. Therefore, we analyzed lymphoma trials initiated between 1 January 2000 and 31 December 2019, using the Trialtrove database and ClinicalTrials.gov. We identified phase 1, 2, and 3 trials that included patients with lymphoma and analyzed the transition rate of investigational agents across phases and their US Food and Drug Administration (FDA) approval rates to assess the efficiency and success of the clinical development process. A total of 1032 phase 1 trials and 510 phase 1/2 trials were conducted, with a total of 651 distinct agents being evaluated during the study period. There were 1027 phase 2, 20 phase 2/3, and 140 phase 3 trials conducted for lymphoma, with 200 agents proceeding from phase 1 to 2 and 46 agents proceeding from phase 2 to 3. The success rates of agents proceeding from phase 1 to 2 and phase 2 to 3 were 30.7% and 23.0%, respectively. A total of 40 agents reached FDA approval, with an overall approval rate of 6.1%. The average time from initiation of the first phase 1 trial to approval for lymphoma treatment was 7.9 years. Our study characterizes the clinical development landscape and timeline of novel therapies for lymphoma. Low approval rate from phase 1 trials in lymphoma suggests the need for improvement in trial design and in prediction of clinical response through preclinical studies to improve the likelihood of success.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.